• SpyBiotech Licenses Selexis’ SUREtechnology for HCMV Vax contractpharma
    March 19, 2021
    Selexis SA, a JSR Life Sciences company, and SpyBiotech, a biotechnology company with a novel vaccine platform, have signed a commercial license agreement to advance SPYVLP102, SpyBiotech’s lead vaccine program for human cytomegalovirus (HCMV).
PharmaSources Customer Service